Brokerages Set OPKO Health, Inc. (NASDAQ:OPK) Target Price at $2.28

Shares of OPKO Health, Inc. (NASDAQ:OPK) have been assigned a consensus recommendation of “Hold” from the seven ratings firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $2.2833.

Several equities research analysts have recently issued reports on OPK shares. Wall Street Zen raised shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Sunday, December 21st. Barrington Research restated an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a research note on Thursday, October 30th. Jefferies Financial Group reaffirmed a “hold” rating and set a $1.60 price objective (down from $2.00) on shares of OPKO Health in a research report on Thursday, October 30th. JPMorgan Chase & Co. initiated coverage on OPKO Health in a report on Thursday, November 20th. They issued a “neutral” rating on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of OPKO Health in a research report on Thursday, January 22nd.

OPKO Health Stock Down 0.8%

OPK stock opened at $1.20 on Friday. The company’s 50 day moving average price is $1.28 and its 200 day moving average price is $1.36. The firm has a market capitalization of $921.24 million, a price-to-earnings ratio of -4.80 and a beta of 1.47. OPKO Health has a fifty-two week low of $1.11 and a fifty-two week high of $2.04. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.32 and a current ratio of 3.70.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. EP Wealth Advisors LLC purchased a new stake in OPKO Health in the fourth quarter valued at $37,000. XTX Topco Ltd purchased a new position in shares of OPKO Health during the fourth quarter worth about $432,000. Zacks Investment Management acquired a new stake in shares of OPKO Health during the fourth quarter worth about $27,000. Quadrature Capital Ltd purchased a new stake in shares of OPKO Health in the 4th quarter valued at about $116,000. Finally, Millennium Management LLC purchased a new stake in shares of OPKO Health in the 4th quarter valued at about $334,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.